Article Text

Download PDFPDF
Treatment of chronic hepatitis E with ribavirin: lessons from deep sequencing
  1. Jérôme Gouttenoire,
  2. Dagmara Szkolnicka,
  3. Darius Moradpour
  1. Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
  1. Correspondence to Professor Darius Moradpour, Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, Lausanne CH-1011, Switzerland; Darius.Moradpour{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Much has been learned about hepatitis E virus (HEV) infection over the last years. We know today that hepatitis E of genotype 3 is a zoonotic infection in the Western world that can be transmitted through the consumption of raw or undercooked pork and game meat, with much higher than anticipated seroprevalence rates, a broad range of hepatic as well as extrahepatic manifestations, and a potential to persist and cause chronic hepatitis as well as cirrhosis in immunocompromised individuals, including transplant recipients as well as patients with haematologic malignancies or poorly controlled HIV infection.1 Fibrosis progression can be rapid in these patients, with a reported 10% developing cirrhosis within 2 years.2 ,3 Reduction of immunosuppressive treatment results in viral elimination in only about 30%.2 ,3 Therefore, antiviral treatment of chronic hepatitis E becomes an important issue. Ribavirin (RBV) is commonly used in this situation.4 However, some patients do not achieve sustained viral elimination even after repeated or prolonged courses and become non-responsive to RBV treatment.

On this background, Todt et al 5 report in this issue an in-depth analysis of HEV genome sequence evolution during RBV treatment of chronic hepatitis E. Using deep sequencing technology, the authors observed in a series of nine patients with chronic HEV genotype 3 infection …

View Full Text


  • Funding The authors acknowledge support by the Swiss National Science Foundation (grant 31003A-156030 to DM) and the Gilead Sciences International Research Scholars Program in Liver Disease (Award 2015 to JG).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • Hepatology
    Daniel Todt Anett Gisa Aleksandar Radonic Andreas Nitsche Patrick Behrendt Pothakamuri Venkata Suneetha Sven Pischke Birgit Bremer Richard J P Brown Michael P Manns Markus Cornberg C Thomas Bock Eike Steinmann Heiner Wedemeyer